MCID: VRR004
MIFTS: 50

Verrucous Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 14 69
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Verrucous Carcinoma Nos 12
Condylomatous Carcinoma 69
Carcinoma, Verrucous 42
Carcinoma Verrucous 52
Warty Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3737
MeSH 42 D018289
NCIt 47 C3781
UMLS 69 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to bladder verrucous squamous cell carcinoma and cervical verrucous carcinoma. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are Pathways in cancer and Mitotic G1-G1/S phases. The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and cervix, and related phenotypes are Decreased viability with paclitaxel and cellular

Wikipedia : 72 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
id Related Disease Score Top Affiliating Genes
1 bladder verrucous squamous cell carcinoma 12.1
2 cervical verrucous carcinoma 12.0
3 esophagus verrucous carcinoma 11.9
4 larynx verrucous carcinoma 11.9
5 glottis verrucous carcinoma 11.9
6 subglottis verrucous carcinoma 11.9
7 supraglottis verrucous carcinoma 11.9
8 vulva verrucous carcinoma 11.9
9 penis non-invasive verrucous carcinoma 11.9
10 urethral verrucous carcinoma 11.8
11 penis verrucous carcinoma 11.8
12 cervical adenoid cystic carcinoma 10.7 CDKN2A TP53
13 split hand split foot nystagmus 10.7 CDKN2A TP53
14 leiomyoma cutis 10.7 CDKN2A TP53
15 anal squamous cell carcinoma 10.7 CDKN2A TP53
16 rnase t2-deficient leukoencephalopathy 10.7 MDM2 TP53
17 breast myoepitheliosis 10.7 CDKN2A TP53
18 ritter's disease 10.7 CDKN2A TP53
19 acute cholinergic dysautonomia 10.7 MDM2 TP53
20 coccidiosis 10.7 CDKN2A TP53
21 adenocarcinoma in situ 10.7 CDKN2A TP53
22 duodenum cancer 10.7 CDKN2A TP53
23 penis paget's disease 10.7 CDKN2A TP53
24 retinal detachment 10.7 CDKN2A TP53
25 larynx carcinoma in situ 10.7 CDKN2A TP53
26 vulvar liposarcoma 10.7 MDM2 TP53
27 phalanx chondroma 10.7 CDKN2A TP53
28 lichen nitidus 10.7 MDM2 TP53
29 olfactory neural tumor 10.7 CDKN2A TP53
30 epidural neoplasm 10.7 CDKN2A MDM2
31 orbital lymphoma 10.7 CDKN2A TP53
32 non-suppurative otitis media 10.7 CDKN2A TP53
33 pancreatic agenesis 10.6 CDKN2A TP53
34 villous adenocarcinoma 10.6 CDKN2A TP53
35 skeletal tuberculosis 10.6 CCND1 CDKN2A
36 animal phobia 10.6 CCND1 TP53
37 spastic ataxia 3 10.6 CDKN2A TP53
38 breast epithelioid hemangioma 10.6 MDM2 TP53
39 esophagus squamous cell carcinoma 10.6 CDKN2A TP53
40 endodermal sinus tumor 10.6 MDM2 TP53
41 pediatric osteosarcoma 10.6 CDKN2A TP53
42 brachial amelia, forebrain defects and facial clefts 10.6 CCND1 CDKN2A
43 chest wall lymphoma 10.6 CCND1 TP53
44 myeloid leukemia 10.6 CCND1 CDKN2A
45 spindle cell liposarcoma 10.6 CDKN2A MDM2
46 sarcomatoid squamous cell skin carcinoma 10.6 CCND1 CDKN2A
47 primary optic atrophy 10.6 CCND1 TP53
48 advanced sleep phase syndrome 10.6 CDKN2A TP53
49 ascaridiasis 10.6 MDM2 TP53
50 juxtacortical chondrosarcoma 10.6 CDKN2A MDM2

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

GenomeRNAi Phenotypes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00293-A 8.8 KRT10 SLC2A1 TP53

MGI Mouse Phenotypes related to Verrucous Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 CDKN2A LRIG1 MDM2 SLC2A1 TP53 TYMP
2 digestive/alimentary MP:0005381 9.72 CCND1 CDKN2A LRIG1 MDM2 TP53
3 nervous system MP:0003631 9.7 CCND1 CDKN2A LRIG1 MDM2 SLC2A1 TP53
4 neoplasm MP:0002006 9.65 CCND1 CDKN2A LRIG1 MDM2 TP53
5 no phenotypic analysis MP:0003012 9.35 CDKN2A LRIG1 MDM2 SLC2A1 TP53
6 skeleton MP:0005390 9.1 CCND1 CDKN2A LRIG1 MDM2 TP53 TYMP

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Doxepin Approved Phase 3 1668-19-5 667477 667468
6
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
7
Bleomycin Approved Phase 3 11056-06-7 5360373
8
Levoleucovorin Approved Phase 3 68538-85-2
9
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
13
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
14
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
15
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
16
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2 216974-75-3
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
19
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
20 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
21 Neurotransmitter Agents Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antimetabolites Phase 3,Phase 2,Phase 1
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
26 Antimitotic Agents Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Antirheumatic Agents Phase 3
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Liver Extracts Phase 3,Phase 2,Phase 1
31 Peripheral Nervous System Agents Phase 3,Phase 2
32 Anti-Infective Agents Phase 2, Phase 3,Phase 1
33 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
34 Autonomic Agents Phase 3,Phase 2
35 Antibodies Phase 3,Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
37 Immunoglobulins Phase 3,Phase 2,Phase 1
38 Antidepressive Agents Phase 3
39 Antidepressive Agents, Tricyclic Phase 3
40 Histamine Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Psychotropic Drugs Phase 3
43 Antidotes Phase 3
44 Calcium, Dietary Phase 3
45
Cobalt Phase 3 7440-48-4 104729
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
49 Protective Agents Phase 3,Phase 2
50 Vitamin B Complex Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 141)

id Name Status NCT ID Phase Drugs
1 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
2 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
3 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
8 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
9 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
10 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
11 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
12 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
13 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
14 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
15 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2 cetuximab;cisplatin
17 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
18 Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Unknown status NCT00721513 Phase 2 cisplatin;docetaxel;fluorouracil
19 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
20 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
21 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
22 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
23 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
24 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
25 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
26 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
27 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
28 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
29 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
30 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
31 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
32 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
33 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
34 Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Completed NCT00738868 Phase 2
35 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
36 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
37 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
38 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
39 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
40 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
41 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
42 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
43 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
44 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
45 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
46 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
47 Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions Recruiting NCT01414426 Phase 2 vandetanib
48 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting NCT02734537 Phase 2 Cisplatin
49 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02295540 Phase 1, Phase 2
50 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT02035527 Phase 1, Phase 2 sorafenib tosylate;cisplatin;docetaxel

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

39
Lung, Skin, Cervix, Brain, Bone, Liver, Lymph Node

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 580)
id Title Authors Year
1
A Giant Cutaneous Horn Projecting from Verrucous Carcinoma of Buccal Mucosa: A Rare Case Report. ( 28511519 )
2017
2
Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma. ( 28621315 )
2017
3
Verrucous carcinoma of the oesophagus. ( 28116819 )
2017
4
Local Excision for the Treatment of Penile Verrucous Carcinoma. ( 28417078 )
2017
5
Verrucous carcinoma of the buccal mucosa with extension to the cheek. ( 28319631 )
2017
6
A clitoral verrucous carcinoma in an area of lichen planus has aggressive features. ( 28061900 )
2017
7
A population-based analysis of verrucous carcinoma of the oral cavity. ( 28850720 )
2017
8
Verrucous carcinoma of the vulva: diagnosis and treatment. ( 28538888 )
2017
9
Rare "Inverted" Verrucous Carcinoma (Carcinoma Cuniculatum) of the Sacrogluteal Region: Case Report and Literature Review. ( 28381141 )
2017
10
Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review. ( 27924463 )
2017
11
Comorbidity between HTLV-1-associated adult T-cell lymphoma/leukemia and verrucous carcinoma: a case report. ( 28559645 )
2017
12
Human Papilloma Virus-Associated Lips Verrucous Carcinoma in HIV-Infected Male. ( 28565927 )
2017
13
Verrucous carcinoma of foot at an unusual site: Lessons to be learnt. ( 28702408 )
2017
14
Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. ( 28150306 )
2017
15
Good Prognosis Went Badly: Fulminant Evolution of a 29-Year-Old Patient with Verrucous Carcinoma of the Cervix. ( 28498727 )
2017
16
Epidemiology and survival outcomes of sinonasal verrucous carcinoma in the United States. ( 28865078 )
2017
17
Laryngeal Verrucous Carcinoma: A Systematic Review. ( 27484231 )
2016
18
The Akt/mTOR pathway is activated in verrucous carcinoma of the oral cavity. ( 26775690 )
2016
19
Verrucous Carcinoma of the Esophagus. ( 27803424 )
2016
20
Subungual Verrucous Carcinoma of the Right Little Finger with Underlying Bony Invasion. ( 27746655 )
2016
21
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature. ( 27307433 )
2016
22
Verrucous carcinoma arising in a port wine stain. ( 26809361 )
2016
23
Verrucous Carcinoma of the Eyelid. ( 27478359 )
2016
24
An Unusual Presentation of Verrucous Carcinoma of the Foot with Bone Invasion. ( 28033059 )
2016
25
Verrucous carcinoma-an enigma: Case report and review. ( 27630507 )
2016
26
A Case of Squamous Cell Carcinoma in the External Auditory Canal Previously Treated for Verrucous Carcinoma. ( 27942606 )
2016
27
Intraosseous verrucous carcinoma arising from an orthokeratinized odontogenic keratocyst: A report of a rarest entity. ( 27630514 )
2016
28
Endoscopic submucosal dissection for an atypical small verrucous carcinoma: a case report. ( 27036299 )
2016
29
Investigation of the association between miRa89181b, Bcla892 and LRIG1 in oral verrucous carcinoma. ( 27509922 )
2016
30
Anal verrucous carcinoma is not related to infection with human papillomaviruses and should be distinguished from giant condyloma (Buschke-LAPwenstein tumor). ( 28012208 )
2016
31
Oral verrucous carcinoma: A retrospective analysis for clinicopathologic features. ( 27072227 )
2016
32
Verrucous Carcinoma of the Vulva: A 20 Year Retrospective Study and Literature Review. ( 26704335 )
2016
33
Oral verrucous hyperplasia versus oral verrucous carcinoma: A clinicopathologic dilemma revisited using p53 as immunohistochemical marker. ( 27721598 )
2016
34
Pyoderma Vegetans Misdiagnosed as Verrucous Carcinoma. ( 26825160 )
2016
35
Bilateral Plantar Verrucous Carcinoma. ( 28035248 )
2016
36
Oral verrucous carcinoma: From multifactorial etiology to diverse treatment regimens (Review). ( 27121637 )
2016
37
Antioxidant enzymes in oral verrucous carcinoma. ( 27245640 )
2016
38
Verrucous Carcinoma of the Vulva: A Case Report and Review of the Literature. ( 26904547 )
2016
39
Reconstruction of the Auricular Defect After Excision of Verrucous Carcinoma. ( 26674896 )
2016
40
Cutaneous leishmaniasis mimicking verrucous carcinoma: A case with an unusual clinical course. ( 25994897 )
2015
41
Association of Macrophages With Angiogenesis in Oral Epithelial Dysplasia, Oral Verrucous Carcinoma, and Oral Squamous Cell Carcinoma: An Immunohistochemical Study. ( 26657870 )
2015
42
Inverted verrucous carcinoma of the buttock mimicking abscess and gossypiboma: MR and pathologic correlation. ( 25957256 )
2015
43
Intraosseous verrucous carcinoma arising from an infected dentigerous cyst-A case report. ( 26254175 )
2015
44
What is your diagnosis? verrucous carcinoma. ( 26367754 )
2015
45
Oral verrucous carcinoma and ameloblastoma: a rare coincidence. ( 25938088 )
2015
46
Reliability of Incision Biopsy for Diagnosis of Oral Verrucous Carcinoma: A Multivariate Clinicopathological Study. ( 26225050 )
2015
47
Expression of Cell Cycle-associated Proteins p53, pRb, p16, p27, and Correlation With Survival: A Comparative Study on Oral Squamous Cell Carcinoma and Verrucous Carcinoma. ( 26447892 )
2015
48
Expression of Matrix Metalloproteinase-10 at Invasive Front of Squamous Cell Carcinoma and Verrucous Carcinoma in the Oral Cavity. ( 26434883 )
2015
49
Human Papillomavirus in Oral Leukoplakia, Verrucous Carcinoma, Squamous Cell Carcinoma, and Normal Mucous Membrane. ( 26674929 )
2015
50
Verrucous Carcinoma with Oral Submucous Fibrosis: A Rare Case with Brief Review. ( 26468468 )
2015

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
id Super pathways Score Top Affiliating Genes
1 12.45 CCND1 CDKN2A MDM2 SLC2A1 TP53
2
Show member pathways
12.44 CCND1 CDKN2A MDM2 TP53
3 12.38 CCND1 CDKN2A MDM2 TP53
4 12.36 CCND1 CDKN2A MDM2 TP53
5 12.29 CCND1 CDKN2A SLC2A1 TP53
6
Show member pathways
12.23 CCND1 CDKN2A MDM2 TP53
7
Show member pathways
12.22 CCND1 MDM2 TP53
8 12.22 CCND1 CDKN2A MDM2 TP53
9
Show member pathways
12.18 CCND1 CDKN2A TP53
10
Show member pathways
12.13 CCND1 MDM2 TP53
11 12.13 CCND1 MDM2 MSN TP53
12 12.11 CCND1 CDKN2A MDM2 TP53
13
Show member pathways
12.09 CCND1 MDM2 TP53
14 11.99 CCND1 MDM2 TP53
15 11.89 CDKN2A MDM2 TP53
16 11.86 CCND1 CDKN2A MDM2 TP53
17 11.82 CDKN2A MDM2 TP53
18 11.77 CCND1 MDM2 SLC2A1 TP53
19 11.73 CCND1 MDM2 TP53
20 11.73 CCND1 CDKN2A MDM2 TP53
21 11.63 CDKN2A MDM2 TP53
22
Show member pathways
11.62 CDKN2A MDM2 TP53
23 11.5 CCND1 CDKN2A MDM2 TP53
24 11.46 CCND1 MDM2 TP53
25 11.42 CCND1 CDKN2A TP53
26 11.31 CCND1 MDM2 TP53
27 11.23 SLC2A1 TP53
28 11.16 CCND1 TP53
29 11.16 CDKN2A MDM2 TP53
30 11.14 MDM2 TP53
31 10.99 CDKN2A MDM2 SLC2A1 TP53
32 10.88 CCND1 CDKN2A MDM2 TP53 TYMP
33 10.84 CDKN2A MDM2 TP53
34
Show member pathways
10.78 CDKN2A MDM2 TP53

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.23 CCND1 CDKN2A KRT10 MDM2 MSN SLC2A1

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 protein complex assembly GO:0006461 9.58 MDM2 SLC2A1 TP53
2 positive regulation of cell cycle GO:0045787 9.57 CCND1 MDM2
3 cellular response to organic substance GO:0071310 9.56 CCND1 MDM2
4 cellular response to glucose starvation GO:0042149 9.55 SLC2A1 TP53
5 response to steroid hormone GO:0048545 9.54 CCND1 MDM2
6 response to antibiotic GO:0046677 9.52 MDM2 TP53
7 cellular response to gamma radiation GO:0071480 9.51 MDM2 TP53
8 response to X-ray GO:0010165 9.49 CCND1 TP53
9 negative regulation of cell cycle arrest GO:0071157 9.48 CCND1 MDM2
10 response to iron ion GO:0010039 9.46 CCND1 MDM2
11 positive regulation of protein export from nucleus GO:0046827 9.43 MDM2 TP53
12 positive regulation of gene expression GO:0010628 9.43 MDM2 MSN TP53
13 response to magnesium ion GO:0032026 9.37 CCND1 MDM2
14 replicative senescence GO:0090399 9.32 CDKN2A TP53
15 mitotic G1 DNA damage checkpoint GO:0031571 9.16 CCND1 TP53
16 amyloid fibril formation GO:1990000 8.65 MDM2
17 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.46 CCND1 CDKN2A MSN TP53
2 SUMO transferase activity GO:0019789 9.26 CDKN2A MDM2
3 enzyme binding GO:0019899 9.26 CCND1 MDM2 MSN TP53
4 disordered domain specific binding GO:0097718 8.62 MDM2 TP53

Sources for Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....